Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors - Trial NCT06408688
Access comprehensive clinical trial information for NCT06408688 through Pure Global AI's free database. This Phase 4 trial is sponsored by University Hospital, Basel, Switzerland and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Basel, Switzerland
Timeline & Enrollment
Phase 4
Jun 01, 2024
Nov 01, 2026
Primary Outcome
Percentage of patients with a relative increase in T cell richness or diversity of 20% or more,Percentage of patients with a relative decrease in T cell clonality of 20% or more,Level of T cell richness,Level of T cell diversity,Level of T cell clonality
Summary
The main objective of this study is to test if adding the mistletoe extract Iscador® Qu to
 regular cancer treatment with immune checkpoint inhibitors affects:
 
 - The immune system's ability to fight cancer
 
 - Safety of the treatment
 
 - How well the treatment performs against cancer
 
 - How the patient feels during treatment
 
 Researchers will compare patients treated with immune checkpoint inhibitors plus Iscador® Qu
 with patients treated with imune checkpoint inhibitors only.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06408688
Non-Device Trial